Compounded Semaglutide vs Tirzepatide: Which to Choose

The two most popular GLP-1 medications for weight loss are semaglutide and tirzepatide. Through Trimi, compounded semaglutide is $99/month and compounded tirzepatide is $125/month. But price is just one factor. Understanding how these medications work differently, their efficacy profiles, side effect patterns, and which patients tend to do better on each can help you and your provider choose the right starting medication.

Quick Comparison

How They Work Differently

Semaglutide: The GLP-1 Specialist

Semaglutide activates a single receptor: GLP-1. This receptor is found in the brain (appetite centers), pancreas (insulin production), stomach (gastric emptying), and other organs. When activated, GLP-1 receptors reduce appetite, slow digestion, improve blood sugar regulation, and create a sense of fullness. Semaglutide is highly potent at the GLP-1 receptor with a long half-life that allows weekly dosing.

Semaglutide has the longest clinical track record among modern GLP-1 medications, with data going back to 2017. The STEP trials demonstrated approximately 15% average body weight loss at the 2.4 mg dose over 68 weeks. Cardiovascular benefits have also been demonstrated in the SELECT trial.

Tirzepatide: The Dual Agonist

Tirzepatide activates two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP receptor activation adds several effects beyond what GLP-1 alone provides: enhanced fat metabolism, improved lipid handling, and amplification of GLP-1's appetite-suppressing effects. This dual mechanism is why tirzepatide consistently outperforms semaglutide in head-to-head comparisons.

The SURMOUNT trials showed tirzepatide at the 15 mg dose produced an average of 22.5% body weight loss over 72 weeks. This represents roughly 50% more weight loss than semaglutide at maximum doses, which is a clinically meaningful difference. Interestingly, tirzepatide also showed somewhat lower rates of nausea compared to semaglutide in clinical trials, likely because the GIP component helps buffer some gastrointestinal effects.

Efficacy Comparison

For a 220-pound person, the average weight loss would be approximately:

• Semaglutide: ~33 pounds (15% of body weight)
• Tirzepatide: ~44-50 pounds (20-22% of body weight)

These are averages from clinical trials. Individual results vary significantly based on diet, exercise, genetics, starting weight, and adherence. Some patients lose more on semaglutide than others do on tirzepatide. The best medication for you is the one that produces results while being tolerable.

Side Effect Profiles

Both medications share similar gastrointestinal side effects, but the rates differ:

• Nausea: Semaglutide ~44%, tirzepatide ~31%
• Diarrhea: Similar rates for both
• Constipation: Slightly higher with tirzepatide
• Vomiting: Similar rates for both
• Injection site reactions: Slightly higher with tirzepatide

The lower nausea rate with tirzepatide is notable because nausea is the most common reason patients discontinue GLP-1 therapy. If you are particularly concerned about nausea, tirzepatide may be the better starting choice.

Cost Analysis

Through Trimi, the cost difference is straightforward:

• Compounded semaglutide: $99/month ($1,188/year)
• Compounded tirzepatide: $125/month ($1,500/year)
• Annual difference: $312

Given tirzepatide's superior average efficacy, the $26/month premium for tirzepatide represents excellent value. However, semaglutide at $99/month is still highly effective and represents the most affordable GLP-1 option available.

Who Should Start with Semaglutide

• Patients who want the most affordable GLP-1 option ($99/month)
• Patients with type 2 diabetes (semaglutide has the most diabetes-specific data)
• Patients who prefer the medication with the longest safety track record
• Patients with moderate weight loss goals (20-40 pounds)
• Patients whose providers recommend starting with a single-agonist approach

Who Should Start with Tirzepatide

• Patients with aggressive weight loss goals (50+ pounds)
• Patients who are particularly concerned about nausea
• Patients who have plateaued on semaglutide
• Patients with significant insulin resistance
• Patients who want the most effective currently available GLP-1 medication

Switching Between Medications

One advantage of using Trimi is the ability to switch between semaglutide and tirzepatide (or retatrutide) within the same program. Common reasons patients switch:

• Semaglutide to tirzepatide: Weight loss plateau, wanting greater efficacy, or persistent side effects on semaglutide
• Tirzepatide to semaglutide: Achieving maintenance weight and wanting to reduce cost, or preferring the single-agonist approach

Your Trimi provider will guide the transition, adjusting doses appropriately based on your current medication and treatment response.

The Bottom Line

Both compounded semaglutide and compounded tirzepatide are excellent weight loss medications available at affordable prices through Trimi. Tirzepatide produces more weight loss on average and may cause less nausea, but costs $26 more per month. Semaglutide has a longer track record and is the most affordable option. Many patients start with semaglutide and switch to tirzepatide if they want more aggressive results.

Visit our treatment options page to get started with either medication. Your Trimi provider will help determine the best starting medication based on your health profile and goals.

Frequently Asked Questions

Is tirzepatide better than semaglutide?

On average, tirzepatide produces more weight loss (20-22% vs 15% body weight) and may cause less nausea. However, individual responses vary, and semaglutide works exceptionally well for many patients. "Better" depends on your specific response, goals, and budget.

Can I start with semaglutide and switch to tirzepatide later?

Yes. Many patients start with semaglutide at $99/month and switch to tirzepatide at $125/month if they want more aggressive weight loss or hit a plateau. Trimi makes this transition seamless within the same program.

Are the side effects different?

Both medications cause similar gastrointestinal side effects, but tirzepatide tends to cause less nausea (31% vs 44%) while possibly causing slightly more constipation. Both improve with time as your body adjusts to the medication.

Which is better for diabetes?

Both medications effectively lower blood sugar. Semaglutide has more long-term diabetes-specific data. Tirzepatide shows superior A1C reduction in head-to-head trials. Discuss with your provider which is most appropriate for your diabetes management.